Our clinical development programs follow rigorous international regulatory standards to ensure safety, efficacy, and transparency across all trial phases.
AlsysLife's clinical development programs are designed to the highest international standards. We follow ICH-GCP guidelines across all our trial phases, ensuring patient safety, data integrity, and regulatory compliance.
Through partnerships with leading hospitals, healthcare institutions, and scientific organizations across Switzerland, the United States, and India, AlsysLife conducts ethically guided clinical trials focused on transforming patient care.
Our trial designs are informed by robust preclinical evidence, biomarker data, and patient insights — ensuring that every study is scientifically sound and patient-centered.
Enquire About TrialsOur ongoing clinical programs focus on delivering safe, effective, and novel therapies for patients with unmet medical needs in autoimmune disease.
International registrational trial evaluating the safety and efficacy of PRC0028 in patients with moderate-to-severe chronic plaque psoriasis. The trial is conducted across multiple sites in Europe, Asia, and the Americas.
Randomized, double-blind, placebo-controlled study evaluating the efficacy of PRC0028 in adult patients with moderate-to-severe atopic dermatitis. Primary endpoints include EASI score improvement and safety profile.
First-in-human study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of BA01 in healthy volunteers and patients with early-stage inflammatory skin disease.
Every clinical trial at AlsysLife is conducted in accordance with the highest ethical and scientific standards to protect patient welfare.
All AlsysLife clinical trials strictly adhere to International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines, ensuring the highest standards of data quality and patient protection.
All trials are reviewed and approved by independent ethics committees and institutional review boards (IRBs) prior to commencement, and patients provide written informed consent before enrollment.
AlsysLife is committed to transparent and timely reporting of clinical trial results, including negative findings, in accordance with international standards for trial registration and results disclosure.
Robust pharmacovigilance systems and data safety monitoring boards (DSMBs) provide independent oversight of all ongoing trials to ensure patient safety throughout the study duration.
AlsysLife is committed to providing access to investigational therapies for patients with serious, life-threatening, or debilitating conditions who cannot access approved treatments and are not eligible for clinical trials.
Our expanded-access programs operate within regulatory frameworks and are evaluated on a case-by-case basis, with patient safety and ethical responsibility as the primary considerations.
Request Information →Healthcare providers seeking information about expanded access should consider: